Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Friday Trading
Asian equities traded in the US as American depositary receipts were moving sharply higher Friday morning, rising 1.2% to 2,061.9 on the S&P Asia 50 ADR Index. With the gain, the index is poised to
BeiGene (NASDAQ:BGNE) Shareholders Have Endured a 55% Loss From Investing in the Stock Three Years Ago
The truth is that if you invest for long enough, you're going to end up with some losing stocks. Long term BeiGene, Ltd. (NASDAQ:BGNE) shareholders know that all too well, since the share price is
When Will BeiGene, Ltd. (NASDAQ:BGNE) Become Profitable?
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A Securities
BeiGene Price Target Cut to $152.50/Share From $180.00 by B of A
BeiGene Is Maintained at Neutral by B of A Securities
BeiGene Is Maintained at Neutral by B of A
B of A Securities Maintains Neutral on BeiGene, Lowers Price Target to $152.5
B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $152.5.
BeiGene Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/09/2024 5.76% B of A Securities $180 → $152.5 Maintains Neutral 05/09/2024 76.14% TD Cowen $236 → $254
Express News | Beigene : BofA Global Research Cuts Price Objective to $152.5 From $180
BofA Securities Maintains BeiGene(BGNE.US) With Hold Rating, Cuts Target Price to $152.5
BofA Securities analyst David Li maintains $BeiGene(BGNE.US)$ with a hold rating, and adjusts the target price from $180 to $152.5.According to TipRanks data, the analyst has a success rate of 16.2%
BeiGene Analysis: Hold Rating Amidst Mixed Drug Sales Performance and Market Competition
Hong Kong stock concept tracking | Innovative drug policy released, medical companies will speed up improvement in the second half of the year (with concept stocks).
Recently, several domestic heavyweight innovative drugs have been approved, and heavyweight data has been successively announced by ASCO, ESMO, ADA, and EHA. The negotiation rules for payment-side medical insurance tend to be clear and mild, and the regulatory side promotes the industry around clinical value. Domestic new drugs have entered the 2.0 era.
Soochow Securities: "Implementation Plan for Supporting the Development of Innovative Drugs Across the Entire Chain" Approved, and the innovative drugs sector is expected to strengthen.
Soochow Securities released research reports stating that the specific provisions of the "Implementation Plan for Full-chain Support of Innovative Drug Development" are expected to be implemented soon. In addition, the innovative drug sector is currently at a historically relatively low level. In the second half of the year, there will be multiple catalysts such as the ESMO conference, WCLC conference, medical insurance negotiations, and expectations for the innovative drug sector going global, which may lead to a strong performance in the innovative drug sector.
Hong Kong stock market concept tracking | Heavy policies supporting the development of innovative drugs are introduced! The industry is expected to enter the fast lane of development (with concept stocks).
On July 5th, the State Council's executive meeting discussed and deployed the work related to promoting high-quality development of the digital economy, and approved the Implementation Plan for Supporting the Development of Innovative Drugs throughout the Whole Chain.
Beigene (06160) issued a total of 0.7363 million shares due to restricted stock units being granted.
Beigene (06160) announced that on June 30, 2024, due to restricted shares granted under the equity plan...
BeiGene Ltd Announces New Stock Grants
Beigene (06160.HK): Granted a total of 1760 American depositary share warrants and 56,600 restricted share units of American depositary shares.
Beigene (06160.HK) announced on July 3, that on June 28, 2024, the board of directors' compensation committee granted options to purchase a total of 1,760 American depositary shares and restricted stock units involving a total of 56,609 American depositary shares to 112 grantees in accordance with the terms of the 2016 equity incentive plan.
BeiGene plans to issue approximately 736,300 shares based on the stock plan.
Beigene (06160) announced that on June 30, 2024, the company issued a total of approximately 736,300 shares in accordance with the stock plan awarded to participants (excluding directors of the issuer) as stock awards or options.
Beigene (06160.HK) received 62.44 million shares due to restricted share unit attribution.
Beigene (06160.HK) announced on July 2 that 624,400 ordinary shares will be issued on June 30, 2024, due to the attribution of restricted share units granted under the equity plan (excluding company directors).
Asian Equities Traded in the US as American Depositary Receipts Open Week on Flat Note
Asian equities traded in the US as American depositary receipts started the week flat Monday morning, nudging 0.005% higher to 1,959.42 on the S&P Asia 50 ADR Index. From North Asia, the gainers were
Moderna And Walgreens Boots Alliance Were Among The 10 Biggest Large Cap Losers Last Week (June 23 - June 29): Are These In Your Portfolio?
These ten large-cap stocks were the worst performers in the last week. Are they in your portfolio?Walgreens Boots Alliance, Inc. (NASDAQ:WBA) shares tumbled 24.12% after the company reported mixed Q3